Article
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.
Blood - 12 Sept 2013
Eckhardt Corien L, van Velzen Alice S, Peters Marjolein, Astermark Jan, Brons Paul P, Castaman Giancarlo, Cnossen Marjon H, Dors Natasja, Escuriola-Ettingshausen Carmen, Hamulyak Karly, Hart Daniel P, Hay Charles R M, Haya Saturnino, van Heerde Waander L, Hermans Cedric, Holmström Margareta, Jimenez-Yuste Victor, Keenan Russell D, Klamroth Robert, Laros-van Gorkom Britta A P, Leebeek Frank W G, Liesner Ri, Mäkipernaa Anne, Male Christoph, Mauser-Bunschoten Evelien, Mazzucconi Maria G, McRae Simon, Meijer Karina, Mitchell Michael, Morfini Massimo, Nijziel Marten, Oldenburg Johannes, Peerlinck Kathelijne, Petrini Pia, Platokouki Helena, Reitter-Pfoertner Sylvia E, Santagostino Elena, Schinco Piercarla, Smiers Frans J, Siegmund Berthold, Tagliaferri Annarita, Yee Thynn T, Kamphuisen Pieter Willem, van der Bom Johanna G, Fijnvandraat Karin
Abstract excerpt
Neutralizing antibodies (inhibitors) toward factor VIII form a severe complication in nonsevere hemophilia A, profoundly aggravating the bleeding pattern. Identification of high-risk patients is hampered by lack of data that take exposure days to therapeutic factor VIII concentrates into account. In the INSIGHT study, we analyzed the association between F8 mutation and inhibitor development in patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.